DC57100 · Updated 27 October 2026
Acuitas A9 Product Datasheet
Print / Save PDF Acuitas A9 is an ionizable lipid corresponding to Compound 9 in US10221127B2. Published mouse studies report hepatic mRNA expression and formulation-dependent inflammatory and tolerability findings. Patent and peer-reviewed data use different LNP compositions and are presented separately.
CAS No. 2036272-50-9 Chemical Name Acuitas A9 Synonyms Lipid A9,Acuitas A9 SMILES CCCCCCCCC(=O)N(CCCN(C)C)C(CCCCCCCCC(=O)OCC(CCCC)CCCCCC)CCCCCCCCC(=O)OCC(CCCC)CCCCCC Formula C57H112N2O5 M.Wt 905.51 Purity >95% by ELSD-HPLC Storage Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light. Shipping condition Ships from Shanghai. Pure lipid is stable during ice-pack transport. Publication Du X, Ansell SM. US10221127B2. Lipids and lipid nanoparticle formulations for delivery of nucleic acids. 5 March 2019. Compound 9; Examples 28–30, Table 3. Holland R, Lam K, Jeng S, et al. Silicon Ether Ionizable Lipids Enable Potent mRNA Lipid Nanoparticles with Rapid Tissue Clearance. ACS Nano 18(15), 10374–10387 (2024). DOI:10.1021/acsnano.3c09028. Table 1, Figures 2–3. Supporting Information Figure S1 and Compound 9 identity entry. Buschmann MD et al. Nanomaterial Delivery Systems for mRNA Vaccines. Vaccines 9(1), 65 (2021). DOI:10.3390/vaccines9010065. Review identity context; reference 59.
Research evidence Read detailed Formulation & Performance
Specifications are catalog specifications, not batch test results.
